In a new initiative that aims to forge broader partnerships between pharma and academia, Eli Lilly has announced that it will conduct free drug development assays in four therapeutic areas on any compounds academic researchers and small biotechs care to send along. In exchange, the company will get first dibs on any licensing deals or collaborations that promising compounds might yield. What differentiates this initiative from the plethora of partnering opportunities out there, Alan Palkowitz, Lilly's vice president of Discovery Chemistry Research & Technologies, told The Scientist, is that "in the initial roll-out this is open to an indefinite number of investigators without any preconditions." The idea, he said, is to work with researchers not just in the US and Europe, but worldwide. The initiative "seems to be very timely," Daphne Zohar, founder and managing partner of linkurl:PureTech Ventures;http://www.puretechventures.com/ in Boston, wrote in an email. "There is a great...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?